anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fatal and serious hypersensitivity reactions including anaphylaxis, presenting with cardiac/ cardiorespiratory arrest, clinically significant hypotension, syncope, or unresponsiveness have occurred in patients receiving Feraheme. Other adverse reactions potentially associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing). These reactions have occurred following the first dose or subsequent doses in patients in whom a previous Feraheme dose was tolerated.

Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products. Carefully consider the potential risks and benefits before administering Feraheme to these patients. 

Only administer Feraheme as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions. Closely observe patients for signs and symptoms of hypersensitivity including monitoring of blood pressure and pulse during and after Feraheme administration for at least 30 minutes and until clinically stable following completion of each infusion [see Adverse Reactions (6.2)]. 

In a clinical study in patients with IDA, regardless of etiology, hypersensitivity reactions were reported in 0.4% (4/997) of subjects receiving Feraheme administered as intravenous infusion over at least 15 minutes. These included one patient with severe hypersensitivity reaction and three patients with moderate hypersensitivity reactions.

In clinical studies predominantly in patients with IDA and CKD, serious hypersensitivity reactions were reported in 0.2% (4/1,806) of subjects receiving Feraheme (administered as a rapid intravenous injection – prior method of administration no longer approved). Other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing) were reported in 3.5% (63/1,806) of these subjects.

In the post-marketing experience, fatal and serious anaphylactic type reactions presenting with cardiac/ cardiorespiratory arrest, clinically significant hypotension, syncope, and unresponsiveness have been reported. Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes [see Boxed Warning, Adverse Reactions (6.2) and Use in Specific Populations (8.5)].
All patients who were placed into a CAM walker boot for \>2 weeks were prospectively enrolled. Patients were placed by an orthopedic cast technician into either a tall or short CAM walker boot, based upon the appropriate boot type needed for treatment. Inclusion criteria included anticipated boot wear for at least two weeks, and weightbearing as tolerated weightbearing restrictions. Exclusion criteria included transitioning into a CAM walker boot as part of a postoperative protocol, injury requiring restricted weightbearing, or an additional acute injury to the lower back or lower extremity. Those who subsequently reported wearing the boot for less than two weeks or had a treatment plan change were removed from the study.
PURPOSE: A composition containing cell permeable sulfiredoxin fusion proteins is provided to suppress and treat inflammation in an animal experiment. CONSTITUTION: A sulfiredoxin fusion protein contains 9-15 amino acid residues. A transduction domain is HIV Tat 49-57 residues, oligolysine, oligoarginine, or oligo(lysine,arginine). The fusion protein has an amino acid sequence of sequence number 7, 9, or 11. A recombinant polypeptide encoding the fusion protein has a transduction domain coding oligonucleotide sequence at one end of sulfiredoxin coding cDNA. A pharmaceutical composition for used as a therapeutic agent for preventing and treating inflammatory dermatitis contains the fusion protein as an active ingredient and pharmaceutically acceptable carrier.
In many bacteria, the essential factors Rho and NusG mediate termination of synthesis of nascent transcripts (including antisense RNAs) that are not being simultaneously translated. It has been proposed that in Rho's absence toxic RNA-DNA hybrids (R-loops) may be generated from nascent untranslated transcripts, and genome-wide mapping studies in Escherichia coli have identified putative loci of R-loop formation from more than 100 endogenous antisense transcripts that are synthesized only in a Rho-deficient strain. Here we provide evidence that engineered expression in wild-type E. coli of several such individual antisense regions on a plasmid or the chromosome generates R-loops that, in an RNase H-modulated manner, serve to disrupt genome integrity. Rho inhibition was associated with increased prevalence of antisense R-loops also in Xanthomonas oryzae pv. oryzae and Caulobacter crescentus. Our results confirm the essential role of Rho in several bacterial genera for prevention of toxic R-loops from pervasive yet cryptic endogenous antisense transcripts. Engineered antisense R-looped regions may be useful for studies on both site-specific impediments to bacterial chromosomal replication and the mechanisms of their resolution.
The experimental group 2 (EG2) intervention combines the psychomotor program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.
BACKGROUND: Atrial fibrillation (AF) risk increases with age. We aim to assess the efficacy and safety of catheter ablation in the older population.
METHODS: All patients undergoing AF ablation (2013-2021) at our institution were enrolled in a prospectively maintained registry. The primary endpoint was AF recurrence. Patients were divided into 3 groups: non-elderly (< 65 years), elderly (65-75 years), and very elderly (> 75 years). Patient surveys at baseline and during follow-up were used to calculate quality of life (QoL) metrics: the AF severity score as well as the AF burden.
RESULTS: A total of 7020 patients were included (42% non-elderly, 42% elderly, and 16% very elderly). Periprocedural major complications were low (< 1.5%) and similar in all groups besides pericardial effusion which was more frequent with older age and similar between the elderly and very elderly. At 3 years, AF recurrence for persistent AF (PersAF) was highest in the very elderly group (48%), followed by the elderly group (42%), and was the lowest in the non-elderly group (36%). In paroxysmal AF (PAF), there was no difference in AF recurrence between the elderly and non-elderly, while the very elderly remained associated with a significantly increased risk. Multivariable Cox analysis confirmed these findings (PersAF; elderly: HR = 1.23, P = 0.003; very elderly: HR = 1.44, P < 0.001) (PAF; elderly: HR = 1.04, P = 0.62; very elderly: HR = 1.30, P = 0.01). Catheter ablation resulted in a significant improvement in quality of life, irrespective of age group.
CONCLUSION: Catheter ablation in elderly and very elderly patients is safe, efficacious, and associated with QoL benefits. Overall, major complications were minimal and did not differ significantly between age groups, with the exception of pericardial effusions which were higher in the elderly and very elderly compared to non-elderly adults. Very elderly patients had a higher rate of AF recurrence when compared with elderly or non-elderly patients. Nevertheless, ablation resulted in a remarkable improvement in QoL and a reduction of AF burden and AF symptoms with a similar magnitude, irrespective of age.
<P>PROBLEM TO BE SOLVED: To increase the electrotransport flux of a polypeptide drug.  <P>SOLUTION: The polypeptide drug is modified to increase its transdermal electrotransport flux. The polypeptide is modified by substituting a histidine residue (His) for one or more glutamine (Gln), threonine (Thr), and/or asparagine (Asn) residues. The His for Gln substitution is particularly preferred from the standpoint of retaining biological activity of the parent polypeptide. A composition containing the modified polypeptide, which is useful for transdermal electrotransport delivery, is also provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The invention discloses five crystal forms of 7-hydroxyl isoflavone, preparation methods thereof, pharmaceutical composition of the methods and a purpose, and particularly relates to five forms including a crystal form A, a crystal form B, a crystal from C, a crystal form D and a crystal form E, wherein the crystal form A, the crystal form B, the crystal form C, the crystal form D and the crystal form E exist under the solid state of a 7-hydroxyl isoflavone compound. The invention particularly relates to the preparation methods of samples of the five crystal forms. The invention further relates to various preparations and the pharmaceutical composition. The various preparations and the pharmaceutical composition are prepared and developed from materials of different crystal forms of the 7-hydroxyl isoflavone, and the materials of the different crystal forms serve as active ingredients. The various preparations and the pharmaceutical composition play a good clinical treatment function on preventing and curing cardiovascular and cerebrovascular diseases, a brittle-bone disease, inflammation, metabolic diseases and other diseases. The crystal forms can affect absorption speed of effective ingredients of the solid medicine in a living body, strengthen or reduce blood concentration in the living body, and accordingly the treatment function of the medicine on a clinic is affected.
Patients will be fitted in a custom immobilization device. A CT simulation scan will then be performed to pinpoint intended radiosurgery target producing a computer optimized radiation plan to be confirmed by planning radiation physicist. Patient will then be placed in their immobilization device and aligned with the treatment planning position. Patient then receives radiosurgery. Treatment delivery will be divided into components of 3-5Gy with repeat CT based localization in between each of these components. For all patients, a nominal prescription dose of 24Gy will be entered into the tomotherapy cost function. Once the plan that provides maximal spinal sparing has been generated, the plan will be renormalized to produce no more than 8Gy (prior RT) or 10Gy (no prior RT) to 0.5cc of spinal cord by dividing the single fraction treatment into fractions of 3-5Gy.
Asthma and Chronic obstructive pulmonary disease (COPD) are the most common chronic airway diseases, and their recurrent episodes or acute exacerbations are the main reasons for the decline in patients' quality of life and heavy economic burden. Based on the of "winter disease being cared in summer", traditional Chinese medicine (TCM) has a long history and wide application in preventing and treating the recurrence of chronic air diseases, with obvious advantages of combining TCM and Western medicine. However, there is a lack of integrated TCM and Western medicine technical schemes for chronic airway based on high-level evidence-based evidence. The Shu Fei Tie developed by our project team is a medical institution preparation that has been used clinically for a long. Therefore, this study conducted a multi-center, large-sample, randomized controlled clinical study of the Shu Fei Tie to prevent the recurrence of asthma and COPD. The study subjects were patients in the remission period of asthma (1332 cases) and the stable period of COPD (980 cases) On the basis of treatment guided by the guidelines, the experimental group was given the Shu Fei Tie, and the control group was given a placebo of theu Fei Tie. The treatment started 10 days before the " the first Fu" and was conducted every 10 days, A total of 5 times, Each treatment lasted 6-8 hours, and the follow-up period was 45 weeks, for a total of 3 cycles (3 years). The outcome indicators were the number of acute attacks per year for asthma and the number of acute exacerbations per year for COPD. The secondary outcome indicators for asthma included Asthma Control Test (ACT) score, the Asthma Control Questionnaire (ACQ), and the Asthma Quality of Life Questionnaire (AQLQ). For COPD, the secondary outcome indicators included clinical symptom scores and lung function. This study scientifically evaluated the clinical efficacy and safety of the Shu Fei Tie reducing the recurrence of chronic airway diseases, identified the advantageous population, elucidated the mechanism of efficacy, and established a technical scheme for preventing and treating the recurrence of chronic airway diseases with the Shu Fei Tie.
OBJECTIVE: Drug-induced sleepiness is a frequent cause of emergency department (ED) visits for frail patients. The aim of this study was to assess the impact of anticholinergic burden on 90-day revisitation risk for frail patients who visit the ED due to drug-induced sleepiness.
METHODS: This was a retrospective study in which patients treated at a fragility care area of an ED who sought consultation for drug-associated sleepiness from June 2020 to June 2021 were included. To evaluate the 90-day revisitation risk factors, a multivariate analysis was performed, including those factors with a p<0.200 from a previous univariate model. A Cox regression model was performed to assess the impact of a high burden on the time until 90-day ED revisitation.
RESULTS: One hundred and forty-eight patients were included (mean age 80.7±12.3 years). The median number of drugs that patients were currently on at emergency admission was eight (range 2-19), while at hospital discharge it was nine (range 2-20), with the median number of central nervous system (CNS) depressant drugs on admission being three (range 1-6). Thirty-five (23.6%) patients revisited the ED 90 days after discharge for sleepiness or agitation. In the multivariate model, a significant association was observed between a high anticholinergic burden during treatment at discharge (OR 3.74, 95% CI 1.36 to 9.71), chronic kidney disease (OR 2.87, 95% CI 1.19 to 6.81), and the risk of 90-day revisitation. Patients with high anticholinergic burden had a shorter time to revisit than those with medium or low anticholinergic burden (HR 1.96, 95% CI 1.05 to 3.99).
CONCLUSIONS: Patients with pharmacological sleepiness and a high anticholinergic burden in their chronic treatment carry a greater risk of revisitation to EDs, and should be considered candidates for specific interventions after visiting these units.
Participants will receive tislelizumab plus gemcitabine and nab-paclitaxel in cycles of 21 days. Non-progressors will plus concurrent radiotherapy during the 3rd cycle of chemotherapy. After 4-6 cycles treatment, Multiple disciplinary team (MDT) will evaluate whether to undergo radical surgery.
<P>PROBLEM TO BE SOLVED: To solve problems: various methods have been tried to grow hair, but they are centered to massage and giving stimulation and they are not essential improvement as they are expected to hold the present state and temporary amelioration.  <P>SOLUTION: Blood flow of subcutaneous blood capillaries becomes good and metabolism of scalp is activated by soaking the head for at least ≥5 minutes in warm high concentration aqueous carbonic acid solution having ≥500ppm carbon dioxide concentration at ≥30°C. It is thought that the subcutaneous blood capillaries develop toward the scalp by continuing the soaking of the head every day, therefore, hair growth is permanently ameliorated by promoting activity of hair roots. A method is provided to easily and conveniently carry out head bathing with the high concentration aqueous carbonic acid solution without a forced posture. The method is to send the high concentration aqueous carbonic acid solution stored in a vessel to the head by pump or the like, bring the warm aqueous carbonic acid solution to flow down on the whole head with the gravity, receive the flown down aqueous carbonic acid solution and return the same to the vessel.  <P>COPYRIGHT: (C)2008,JPO&INPIT
BACKGROUND: Rice blast and bacterial leaf blight (BLB) are the most limiting factors for rice production in the world which cause yield losses typically ranging from 20 to 30% and can be as high as 50% in some areas of Asia especially India under severe infection conditions.
METHODS AND RESULTS: An improved line of Tellahamsa, TH-625-491 having two BLB resistance genes (xa13 and Xa21) and two blast resistance genes (Pi54 and Pi1) with 95% Tellahamsa genome was used in the present study. TH-625-491 was validated for all four target genes and was used for backcrossing with Tellahamsa. Seventeen IBC1F1 plants heterozygous for all four target genes, 19 IBC1F2 plants homozygous for four, three and two gene combinations and 19 IBC1F2:3 plants also homozygous for four, three and two gene combinations were observed. Among seventeen IBC1F1 plants, IBC1F1-62 plant recorded highest recurrent parent genome (97.5%) covering 75 polymorphic markers. Out of the total of 920 IBC1F2 plants screened, 19 homozygous plants were homozygous for four, three and two target genes along with bacterial blight resistance. Background analysis was done in all 19 homozygous IBC1F2 plants possessing BLB resistance (possessing xa13, Xa21, Pi54 and Pi1 in different combinations) with five parental polymorphic SSR markers. IBC1F2-62-515 recovered 98.5% recurrent parent genome. The four, three and two gene pyramided lines of Tellahamsa exhibited varying resistance to blast.
CONCLUSIONS: Results show that there might be presence of antagonistic effect between bacterial blight and blast resistance genes since the lines with Pi54 and Pi1 combination are showing better resistance than the combinations with both bacterial blight and blast resistance genes.
Patients with cancer pain are frequently under-medicated with morphine. This is a 56-day open-label study of the efficacy and safety of self-administered fentanyl skin patches for cancer pain control in patients in the home-care setting not previously using morphine. The first 15 days of the study are for dose stabilization and the rest of the study assesses pain control and quality of life at stable doses of medication. The dose is determined by the patient with oversight by the investigator, and rescue oral morphine medication can be used when necessary. The patient records all medication use in a diary and fills out questionnaires concerning pain control, intestinal function (constipation) and overall quality of life. The hypothesis is that patients will be able to control their cancer pain by self-administering transdermal fentanyl at home and that they will well tolerate the medication.

Individualized doses, with a target dose of 25 to 100 micrograms per hour of fentanyl for 56 days via skin patches applied every 3 days to deliver 25 to 100 micrograms of fentanyl per hour per patch; oral morphine as rescue medication for pain.
PURPOSE:To obtain the titled suppository, rich in elution property and having high safety and blood concentration level, by dissolving insulin, an absorption accelerator and/or water-soluble saccharide at a specific blending ratio in water, drying the resultant solution, blending the obtained powder with a base and forming the blend. CONSTITUTION:An insulin suppository obtained by dissolving insulin in an amount of 0.1-1wt% based on the suppository, an absorption accelerator, e.g. a compound expressed by formula I (R is H, OH, etc.) or a compound expressed by formula II (X is Cl, Br) in an amount of 2-5wt% based on the suppository and/or a water-soluble saccharide, e.g. lactose or mannitol, in an amount of 0.5-30wt% based on the suppository in water, drying the resultant solution, blending the resultant powder with a base and forming the blend. The above- mentioned method provides a high dissolution rate of the insulin from the suppos itory and good safety. Furthermore, the content is uniform and release of the absorption accelerator can be controlled to sustain the insulin concentration in blood serum at a high level.
OXYGEN 2 NON-FLAMMABLE GAS 2 Compressed gas, oxidizing, n.o.s. (Oxygen, Nitrogen) UN3156 Medical Gas Mixture 50% Oxygen, USP CAS: 7782-44-7 Balance Nitrogen, NF CAS: 7727-37-9 CAUTION: Federal law prohibits dispensing without a prescription. Rx only. WARNING: OXIDIZIN HIGH PRESSURE GAS. VIGOROUSLY ACCELERATES COMBUSTION. Keep oil and grease away. Use only with equipment cleaned for oxygen service and rated for cylinder pressure. Use equipment rated for cylinder pressure. Store and use with adequate ventilation. Close valve after each use and when empty. Open valve slowly. Administration of this gas mixture may be hazardous or contraindicated. For use only by or under the supervision of a licensed practitioner who is experienced in the use and administration of gas mixtures and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications and side effects and the precautions to be taken. Use in accordance with the appropriate MSDS for each mixture component. Secure cylinder while in transportation, storage and in use. Serial Number: 49284750 In Emergency Call: 1-800-494-9300 Lot No.: 338sci12dp1 - Volume: 200 - Exp. Date: 12/11/17 Label #: HC101 December 12, 2012 Ver. 2.33 For Medical Use Only. Spec Connection International Inc 37325 sr 54 Zephyrhills FL 33542 Ph# 813-997-8950 DO NOT REMOVE THIS PRODUCT LABEL

Revised: 12/2012

Document Id: 4619d090-d857-48e3-94aa-8bb2478e43d0

Set id: be67a0a6-da55-418e-89c6-a82b267b07da

Version: 1

Effective Time: 20121227

Spec Connection International Inc
PURPOSE:An ointment useful for preventing skin inflammations such as bedsore, prickly heat, etc. and remedying them in an early stage, absorbing sweat, dissolving it gradually, neutralizing acidity of sweat, keeping the skin weakly alkali, containing lime carbonate of Aragonite type. CONSTITUTION:An ointment capable of preventing occurrence of skin inflammations and bedsore, containing lime carbonate of Aragonite type. Its content is properly 3-15(W/W)%. Lime carbonate of Aragonite type derived from Aragonite, calcareous tufa, coral, etc. may be used as the line carbonate of Aragonite type. The lime carbonate of Aragonite absorbs sweat, dissolves it gradually, neutralizes acidity of sweat, and keeps the skin weakly alkali. Moreover, neutralizing effect continues, so the ointment is extremely effective for preventing skin inflammations such as bedsore, prickly heat, etc. and remedying them in an early stage.
Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
Methods: This study uses a synchronized Tandem VR approach where patient- caregiver dyads experience immersive nature-based and other outdoor VR content. This mixed methods study will recruit 20 patient-caregiver dyads (N = 40) enrolled in home hospice services nearing the end-of-life. Dyads will experience a personalized nature-based or other outdoor VR experience lasting 5-15 minutes. Self-reported questionnaires and semi-structured interviews will be collected before and after the VR intervention to identify the impacts of personalized nature-based and other outdoor Tandem VR experiences on the QOL, pain, and fear of death in patient-caregiver dyads enrolled with hospice services. Additionally, this protocol will determine the acceptance of personalized nature-based and other outdoor Tandem VR experiences by dyads as a non-pharmacological modality for addressing patient and caregiver needs. Acceptance was quantified by the number of dyads accepting or declining the VR experience during recruitment.

Discussion: Using personalized, nature-based and other outdoor VR experiences, the patient-caregiver dyads can simultaneously engage in an immersive encounter to help alleviate symptoms associated with declining health and EOL phases for the patient and the often overburdened caregiver. This protocol focuses on meeting the need for person- and caregiver-centered, non-pharmacological interventions to reduce physical, psychological, and spiritual distress.